InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
58,611.16
(
1.24%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: keitern post# 2593

Wednesday, 01/31/2007 9:00:28 AM

Wednesday, January 31, 2007 9:00:28 AM

Post# of 19309
If a drug derived from the milk of transgenic animals is commercialized, GTC will presumably seek to license its “milk” patent for an up-front fee and/or a royalty on sales. The terms will have to be negotiated.

Research and clinical-trial use of a drug candidate is exempt from U.S. patent infringement, so there isn’t much for the parties to talk about until such a drug is commercialized or on the verge of being commercialized. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up